Immune Checkpoint Inhibitors and Kidney Disease - Dr. Herrmann (Rochester)

Dr. Sandra Herrmann from Mayo Clinic in Rochester discusses the potential renal adverse effects of Immune Checkpoint Inhibitors (ICI) in oncologic patients. Dr. Herrmann is a Nephrologist and Associate Professor of Medicine. Her major field of clinical and academic work is onconephrology, with a focus on the risk of acute kidney disease and electrolyte disorders in patients on ICI.

The interview was recorded on March 21st, 2022. Moderators: Prof. Dr. Dominik Wolf (Innsbruck, Austria), Priv.-Doz. Dr. Andreas Kronbichler (Cambridge, UK / Innsbruck, Austria) and Prof. Dr. Gunnar Heine (Frankfurt / Homburg, Germany).

Articles discussed:

Renal Tubular Acidosis and Immune Checkpoint Inhibitor Therapy: An Immune-Related Adverse Event of PD-1 Inhibitor-A Report of 3 Cases.
Herrmann SM, et al. Kidney Med. 2020. PMID: 33089143

Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events.
Isik B, …, Herrmann SM. Kidney Int Rep. 2021 doi: 10.1016/j.ekir.2021.01.013.

Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB, et al. J Am Soc Nephrol. 2020. PMID: 31896554

Acute kidney injury in patients treated with immune checkpoint inhibitors.
Gupta S, et al. J Immunother Cancer. 2021. PMID: 34625513